Leptin, ghrelin, and endocannabinoids: potential therapeutic targets in anorexia nervosa.

Author(s): Støving RK, Andries A, Brixen K, Flyvbjerg A, Hørder K, Frystyk J

Center for Eating Disorders and Department of Endocrinology, Odense University Hospital, DK-5000 Odense, Denmark. [email protected]

Subject: Anorexia View the study

Abstract:

Anorexia nervosa (AN) has the highest mortality rate between psychiatric disorders, and evidence for managing it is still very limited. So far, pharmacological treatment has focused on a narrow range of drugs and only a few controlled studies have been performed. Furthermore, the studies have been of short duration and included a limited number of subjects, often heterogenic with regard to stage and acute nutritive status. Thus, novel approaches are urgently needed. Body weight homeostasis is tightly regulated throughout life. With the discovery of orexigenic and anorectic signals, an array of new molecular targets to control eating behavior has emerged.

Source: Journal of Psychiatric Research (Price: $36)
Share Tweet

More medical studies related to Anorexia:

View all medical studies >>

Subscribe for daily cannabis news, announcements, and business insights.

вывоз строительного мусора в киеве

Путівки на мальдіви у нас
https://velotime.com.ua/